Dr. Jason Melear, M.D.
What this data tells you about Dr. Melear
Dr. Jason Melear is a medical oncology specialist in Austin, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Melear performed 26,799 Medicare services across 2,747 unique beneficiaries.
Between the years covered by Open Payments, Dr. Melear received a total of $239,212 from 45 pharmaceutical and/or device companies across 328 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Melear is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia | 8,725 | $2 | $20 |
| Iron sucrose injection (Venofer) | 7,300 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 2,580 | $19 | $67 |
| Dexamethasone injection (steroid) | 1,099 | $0 | $1 |
| Blood draw (venipuncture) | 997 | $8 | $20 |
| Complete blood count (CBC) with differential | 810 | $8 | $36 |
| Comprehensive metabolic blood panel | 730 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 520 | $0 | $24 |
| Measurement of immunoglobulin light chains | 428 | $17 | $60 |
| Office visit, established patient (30-39 min) | 346 | $93 | $368 |
| Office visit, established patient (20-29 min) | 327 | $62 | $250 |
| Microscopic examination for white blood cells with manual cell count | 194 | $4 | $22 |
| Complete blood count (CBC), automated | 194 | $6 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 191 | $24 | $157 |
| Office visit, established patient, complex (40-54 min) | 170 | $133 | $496 |
| Administration of chemotherapy into vein, 1 hour or less | 166 | $107 | $707 |
| Lactate dehydrogenase (enzyme) level | 139 | $6 | $31 |
| Reticulated (young) platelet measurement | 134 | $35 | $143 |
| Protein measurement, serum | 125 | $11 | $99 |
| Injection, zoledronic acid, 1 mg | 113 | $6 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 105 | $51 | $313 |
| Ferritin level test (iron stores) | 103 | $13 | $60 |
| Immunoglobulin level test | 102 | $9 | $56 |
| Drug injection, under skin or into muscle | 89 | $11 | $96 |
| Administration of chemotherapy into vein, each additional hour | 89 | $23 | $161 |
| Infusion, normal saline solution , 1000 cc | 87 | $2 | $19 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 81 | $20 | $128 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 76 | $60 | $211 |
| Injection of additional new drug or substance into vein | 74 | $12 | $108 |
| Injection, diphenhydramine hcl, up to 50 mg | 70 | $1 | $7 |
| Iron level test | 52 | $6 | $27 |
| Iron binding capacity test | 52 | $8 | $35 |
| Infusion into a vein for hydration, each additional hour | 52 | $10 | $75 |
| Carcinoembryonic antigen (cea) protein level | 50 | $18 | $99 |
| Administration of additional new drug or substance into vein, 1 hour or less | 49 | $53 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 48 | $17 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $26 | $145 |
| Infusion into a vein for hydration, 31-60 minutes | 35 | $27 | $256 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 35 | $344 | $1,722 |
| Administration of additional new drug or substance into vein using push technique | 30 | $46 | $289 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 23 | $90 | $657 |
| Unclassified drugs | 23 | $1 | $8 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 23 | $1 | $19 |
| Injection of drug or substance into vein | 20 | $31 | $247 |
| New patient office visit (45-59 min) | 16 | $118 | $565 |
| New patient office visit, complex (60-74 min) | 16 | $163 | $709 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 15 | $1,229 | $4,802 |
| New patient office visit (30-44 min) | 15 | $89 | $372 |
| Hospital follow-up visit, low complexity | 14 | $39 | $135 |
| Initial hospital admission, high complexity | 13 | $136 | $694 |
| Drawing of blood for a medical problem | 12 | $72 | $264 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (86%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for medical oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Melear is a mixed practice specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 8% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Melear experienced with darbepoetin injection (aranesp) for anemia?
Does Dr. Melear receive payments from pharmaceutical companies?
How do Dr. Melear's costs compare to other medical oncologists in Austin?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology